167 related articles for article (PubMed ID: 30901735)
1. P2X7 purinoceptor as a therapeutic target in muscular dystrophies.
Górecki DC
Curr Opin Pharmacol; 2019 Aug; 47():40-45. PubMed ID: 30901735
[TBL] [Abstract][Full Text] [Related]
2. The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies.
Zabłocki K; Górecki DC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298386
[TBL] [Abstract][Full Text] [Related]
3. The P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies.
Gόrecki DC; Rumney RMH
Curr Opin Pharmacol; 2023 Apr; 69():102357. PubMed ID: 36842388
[TBL] [Abstract][Full Text] [Related]
4. Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism.
Al-Khalidi R; Panicucci C; Cox P; Chira N; Róg J; Young CNJ; McGeehan RE; Ambati K; Ambati J; Zabłocki K; Gazzerro E; Arkle S; Bruno C; Górecki DC
Acta Neuropathol Commun; 2018 Apr; 6(1):27. PubMed ID: 29642926
[TBL] [Abstract][Full Text] [Related]
5. eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases.
Panicucci C; Raffaghello L; Bruzzone S; Baratto S; Principi E; Minetti C; Gazzerro E; Bruno C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825102
[TBL] [Abstract][Full Text] [Related]
6. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN; Sinadinos A; Lefebvre A; Chan P; Arkle S; Vaudry D; Gorecki DC
Autophagy; 2015; 11(1):113-30. PubMed ID: 25700737
[TBL] [Abstract][Full Text] [Related]
7. Aberrant Adenosine Triphosphate Release and Impairment of P2Y2-Mediated Signaling in Sarcoglycanopathies.
Benzi A; Baratto S; Astigiano C; Sturla L; Panicucci C; Mamchaoui K; Raffaghello L; Bruzzone S; Gazzerro E; Bruno C
Lab Invest; 2023 Mar; 103(3):100037. PubMed ID: 36925196
[TBL] [Abstract][Full Text] [Related]
8. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
[TBL] [Abstract][Full Text] [Related]
9. The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan-Deficient Muscular Dystrophy.
Gazzerro E; Baratto S; Assereto S; Baldassari S; Panicucci C; Raffaghello L; Scudieri P; De Battista D; Fiorillo C; Volpi S; Chaabane L; Malnati M; Messina G; Bruzzone S; Traggiai E; Grassi F; Minetti C; Bruno C
Am J Pathol; 2019 Feb; 189(2):354-369. PubMed ID: 30448410
[TBL] [Abstract][Full Text] [Related]
10. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.
Young CN; Brutkowski W; Lien CF; Arkle S; Lochmüller H; Zabłocki K; Górecki DC
J Cell Mol Med; 2012 May; 16(5):1026-37. PubMed ID: 21794079
[TBL] [Abstract][Full Text] [Related]
11. P2X7 Purinoceptor Affects Ectopic Calcification of Dystrophic Muscles.
Rumney RMH; Róg J; Chira N; Kao AP; Al-Khalidi R; Górecki DC
Front Pharmacol; 2022; 13():935804. PubMed ID: 35910348
[TBL] [Abstract][Full Text] [Related]
12. Dystrophin: The dead calm of a dogma.
Górecki DC
Rare Dis; 2016; 4(1):e1153777. PubMed ID: 27141413
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of Muscle T Regulatory Cells and Improvement of Muscular Dystrophic Process in mdx Mice by Blockade of Extracellular ATP/P2X Axis.
Gazzerro E; Baldassari S; Assereto S; Fruscione F; Pistorio A; Panicucci C; Volpi S; Perruzza L; Fiorillo C; Minetti C; Traggiai E; Grassi F; Bruno C
Am J Pathol; 2015 Dec; 185(12):3349-60. PubMed ID: 26465071
[TBL] [Abstract][Full Text] [Related]
14. Increased susceptibility to ATP via alteration of P2X receptor function in dystrophic mdx mouse muscle cells.
Yeung D; Zablocki K; Lien CF; Jiang T; Arkle S; Brutkowski W; Brown J; Lochmuller H; Simon J; Barnard EA; Górecki DC
FASEB J; 2006 Apr; 20(6):610-20. PubMed ID: 16581969
[TBL] [Abstract][Full Text] [Related]
15. Fast skeletal myofibers of mdx mouse, model of Duchenne muscular dystrophy, express connexin hemichannels that lead to apoptosis.
Cea LA; Puebla C; Cisterna BA; Escamilla R; Vargas AA; Frank M; Martínez-Montero P; Prior C; Molano J; Esteban-Rodríguez I; Pascual I; Gallano P; Lorenzo G; Pian H; Barrio LC; Willecke K; Sáez JC
Cell Mol Life Sci; 2016 Jul; 73(13):2583-99. PubMed ID: 26803842
[TBL] [Abstract][Full Text] [Related]
16. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the anti-IL-6 receptor antibody attenuates muscular dystrophy via promoting skeletal muscle regeneration in dystrophin-/utrophin-deficient mice.
Wada E; Tanihata J; Iwamura A; Takeda S; Hayashi YK; Matsuda R
Skelet Muscle; 2017 Oct; 7(1):23. PubMed ID: 29078808
[TBL] [Abstract][Full Text] [Related]
18. Impact of P2RX7 ablation on the morphological, mechanical and tissue properties of bones in a murine model of duchenne muscular dystrophy.
Mohamad NS; Sinadinos A; Górecki DC; Zioupos P; Tong J
J Biomech; 2016 Oct; 49(14):3444-3451. PubMed ID: 27663621
[TBL] [Abstract][Full Text] [Related]
19. P2X7 receptor antagonism in the treatment of cancers.
Roger S; Pelegrin P
Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470
[TBL] [Abstract][Full Text] [Related]
20. Specific Dystrophins Selectively Associate with Inhibitory and Excitatory Synapses of the Mouse Cerebellum and their Loss Alters Expression of P2X7 Purinoceptors and Pro-Inflammatory Mediators.
Jackson T; Seifi M; Górecki DC; Swinny JD
Cell Mol Neurobiol; 2022 Oct; 42(7):2357-2377. PubMed ID: 34101068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
